Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Oncology

Articles with lock require a GLG News subscription
Posted March 19, 2008
Pfizer to Acquire Serenex to Extend Oncology Pipeline and Access Novel Technology Platform
Analysis of: Pfizer to Acquire Serenex to Extend Oncology Pipeline and Access Novel Technology Platform | www.pipelinereview.com
Author: GLG Member Program Contributor
The identification of novel molecular targets the targeting of which might generate satisfactory anti-cancer results is by no means optimistic.
Posted March 17, 2008
FDA Panel Backs Anemia Drugs For Cancer Patients, but With Limits
Analysis of: FDA Panel Backs Anemia Drugs For Cancer Patients, but With Limits | online.wsj.com
Author: GLG Member Program Contributor
FDA panel recommended these new instructions after the failure and the over-estimated design of previous conducted clinical trials
Posted March 14, 2008
FDA Panel Backs Anemia Drugs For Cancer Patients, but With Limits
Analysis of: FDA Panel Backs Anemia Drugs For Cancer Patients, but With Limits | online.wsj.com
Author: GLG Member Program Contributor
Epo products (Aranesp, Procrit, Epogen) from Amgen and J & J will be restricted to some degree with control of hemoglobin levels, NO use in curable malignancies ..." the panel voted 11 to 2 in recommending that the drugs not be used in cancer patients who are likely to be cured from their...
Posted March 14, 2008
FDA Panel Backs Anemia Drugs For Cancer Patients, but With Limits
Analysis of: FDA Panel Backs Anemia Drugs For Cancer Patients, but With Limits | online.wsj.com
Author: GLG Member Program Contributor
An FDA panel recommended NOT to use ESA's for treatment of chemotherapy induced anemia in Breast cancer patients and head and neck acncer patients, a significant number of cancer patients. It also voted overwhelmingly to limit ESA's for non-curable cancer patients in the setting of palliative care....
Posted March 12, 2008
Teva Announces Approval Of Generic Camptosar(R)
Analysis of: Teva Announces Approval Of Generic Camptosar(R) | www.pipelinereview.com
Author: GLG Member Program Contributor
The article does not tell if TEVA was the first generic to market. Certainly being generic TEVA will gain some market share from Pfizer
Posted March 11, 2008
The High Cost of a Cancer Drug
Analysis of: The High Cost of a Cancer Drug | www.nytimes.com
Author: GLG Member Program Contributor
FDA's approval of Genentech's Avastin is backed both by efficacy data and aggressive political activism. Extension of PFS by almost 6 months and shrinking large tumors, thus improving quality of life, are tangible and real beneficial effects. Avastin was already being prescribed off-label. The approval...
Posted March 11, 2008
Teva Announces Approval Of Generic Camptosar(R)
Analysis of: Teva Announces Approval Of Generic Camptosar(R) | www.pipelinereview.com
Author: GLG Member Program Contributor
Is it possible to lower the cost of chemotherapy by using generics or biosimilar? What will be the consequence in efficacy and toxicity?
Posted March 10, 2008
The High Cost of a Cancer Drug
Analysis of: The High Cost of a Cancer Drug | www.nytimes.com
Author: GLG Member Program Contributor
Metastatic breast cancer is incurable with a trend for increasing survival with the use of new agents. Why time to disease progression was used instead of overall survival as it happened in all other Bevacizumab-based clinical trials in other solid tumors?
Posted March 10, 2008
The High Cost of a Cancer Drug
Analysis of: The High Cost of a Cancer Drug | www.nytimes.com
Author: GLG Member Program Contributor
This editorial is questioning the use of this expensive agent in patients with metastatic breast cancer when it only increases time to progression 5.5 months.
Posted March 10, 2008
Teva Announces Approval Of Generic Camptosar(R)
Analysis of: Teva Announces Approval Of Generic Camptosar(R) | www.pipelinereview.com
Author: GLG Member Program Contributor
Pfizer's Irinotecan ( CPT-11) is mostly used in colorectal cancer with some limited use in sarcomas, glioblastoma multiforme, and other solid tumors. Teva's generic compound is expected to be cheaper, and with current economic situation, may be mandated by third party payers to cut costs, and this will...
Previous Page : 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 Next151 to 160 of 717

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics